FDA Approves First Generic Injectable Lenacapavir for HIV Prevention

The U.S. FDA has approved the first generic injectable lenacapavir, a twice-yearly HIV prevention medication. This approval for Dr. Reddy's Laboratories, coming shortly after the originator product, is expected to significantly enhance access to affordable HIV prevention in 120 low- and middle-income countries. Initial supplies are anticipated by late 2026, marking a major step in global health equity.